WP
ABEO icon

Woodline Partners’s Abeona Therapeutics ABEO Stock Holding History

Woodline Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-43,256
Closed -$1.1M – 217
2020
Q3 		$1.1M Sell
43,256
-12,978
-23% -$818K 0.04% 170
2020
Q2 		$4.1M Buy
56,234
+7,901
+16% +$546K 0.16% 121
2020
Q1 		$2.54M Buy
48,333
+16,443
+52% +$1.1M 0.18% 111
2019
Q4 		$2.61M Buy
+31,890
New +$2.25M 0.11% 100

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Woodline Partners's ABEO Position: Q4 2020 in Review

Woodline Partners sold out of Abeona Therapeutics (ABEO) in Q4 2020, closing a stake of 43,256 shares — an estimated $1.1M sold.

Woodline Partners first reported a position in ABEO in Q4 2019 and held it in 4 quarters. The position peaked at $4.1M in Q2 2020. 73 funds tracked by Wall St. Rank hold ABEO as of Q4 2020.

  • Woodline Partners reported no remaining Abeona Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Woodline Partners sold 43,256 Abeona Therapeutics shares in Q4 2020, an estimated $1.1M.
  • Woodline Partners first reported a position in Abeona Therapeutics in Q4 2019 and held it in 4 quarters.
  • Woodline Partners's Abeona Therapeutics position peaked at $4.1M in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2020.

Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.